Michael Keating

Michael Keating is a foundational figure in CLL therapy who contributed to development of fludarabine-based chemotherapy and alemtuzumab that defined treatment standards for decades before targeted therapies. He has cared for thousands of CLL patients over his career and contributed to understanding of CLL biology, natural history, and the impact of genetic aberrations on prognosis. His clinical observations and translational studies laid groundwork for modern targeted therapy development. He is a recipient of the ASH Lifetime Achievement Award and has mentored a generation of CLL specialists.